bmn-673 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

bmn-673 has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 1 studies

Other Studies

1 other study(ies) available for bmn-673 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

ArticleYear
PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Line, Tumor; Coculture Techniques; DNA Breaks, Double-Stranded; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Phthalazines; Poly (ADP-Ribose) Polymerase-1; Tumor Microenvironment; Xenograft Model Antitumor Assays

2019